Here, we first prove that METTL3 is highly expressed in pancreatic cancer and inhibits ferroptosis-induced gemcitabine resistance, and HMGB1 is identified as a downstream target of METTL3. The gene discussed is METTL3; the disease is pancreatic neoplasm.